Five things for pharma marketers to know: Tuesday, November 21, 2017

Share this content:


1. Johnson & Johnson plans to hold a meeting to discuss strategies to maintain the market share of rheumatoid arthritis drug Remicade. The company has requested advice from medical experts to “identify opportunities to differentiate Remicade.” Remicade faces biosimilar competition from Samsung Bioepis' Renflexis and Pfizer/Celltrion's Inflectra. (STAT)

2. Acorda Therapeutics has decided to discontinue development of its experimental Parkinson's disease drug tozadenant. Five patients died from sepsis in a clinical trial while taking the drug. (Endpoints News)

3. New data show that Johnson & Johnson's multiple-myeloma drug Darzalex, when taken in combination with Takeda Pharmaceuticals' Velcade, a steroid, and chemotherapy, reduced the risk of death and disease progression by 50% compared to patients taking the same combination without Darzalex. This data could lead to the drug's approval as a first-line treatment. (Reuters)

4. President Trump's Department of Health and Human Services secretary nominee Alex Azar built a financial portfolio worth more than $20 million while he worked at Eli Lilly. He was paid almost $2 million during his final year at the company. (AP)

5. Concordia overcharged Britain's National Health Service by $45 million for its thyroid drug liothyronine, according to Britain's Competition and Markets Authority. (Reuters)

Share this content:
Scroll down to see the next article